Management

This page includes content on healthcare management, including health system, hospital, department and clinic business management and administration. Areas of focus are on cardiology and radiology department business administration. Subcategories covered in this section include healthcare economics, reimbursement, leadership, mergers and acquisitions, policy and regulations, practice management, quality, staffing, and supply chain.

RSS icon
Thumbnail

ACA critic, Minnesota health economist Stephen Parente appointed to leadership post at HHS

Stephen Parente, PhD, MPH, MS, brings a long resume as a health economist and policy expert. He’s spent the last 17 years at the University of Minnesota, currently holding the title of Minnesota Insurance Industry Chair of Health Finance in the Carlson School of Management and director of the school’s Medical Industry Leadership Institute.

Online tool expands measurements to predict risk of heart disease, diabetes

Predicting a patient's risk for developing heart disease or diabetes can be like looking into a crystal ball. Such a tool is now an online reality thanks to a team of researchers from the University of Virginia School (UVA) of Medicine and the University of Florida.

Amazon Alexa challenge combines diabetes management, voice technology

The Alexa Diabetes Challenge, launched April 10, is searching for innovators to improve the capabilities of the Amazon Alexa voice-enabled device to assist users with type 2 diabetes. The multi-stage competition, sponsored by Merck & Co. and supported by Amazon Web Services, is offering $250,000 in total in prizes.

EHRs blamed for hundreds of medication errors in Pennsylvania

In the first half of 2016, 889 medication errors or close calls in Pennsylvania hospitals could have been attributed to electronic health records or other monitoring technology, according to the Pittsburgh Post-Gazette. 

Thumbnail

S&P: ACA markets ‘fragile'—but not in death spiral

Despite claims by President Donald Trump, Republican members of Congress, and some insurance CEOs, the Affordable Care Act (ACA)’s health insurance exchanges aren’t in a death spiral, according to a Standard and Poor’s (S&P) analysis, which predicts the individual market is actually on a path to profitability in 2018.

FDA approves two hepatitis C drugs for pediatric patients

The U.S. Food and Drug Administration (FDA) has approved Sovaldi (sofosbuvir) and Harvoni (ledipasvir and sofosbuvir) for the treatment of hepatitis C in pediatric patients, ages 12 to 17.

Thumbnail

Improving patient experience is not ‘just about making the patients happy’

Bon Secours Baltimore Health System has been called a facility “in the worst of America’s healthcare system,” serving the same areas depicted in the HBO crime drama “The Wire” and near the site of riots in 2015. 

Contacting patients before surgery cuts cancellations in half

Cancelling a preplanned surgery, especially in ambulatory care, costs hospitals money and resources and wastes time. A recent study, published in AORN, looked at how contacting patients by phone before surgery can reduce the number of cancellations. 

Displaying 4777 - 4784 of 6647

Around the web

Cardiovascular Business
Q&A: Why are cardiovascular devices involved in so many recalls? FDA policies may be to blame

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Cardiovascular Business
Cardiologist compensation still rising, especially in invasive and interventional cardiology

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

Cardiovascular Business
FDA’s tirzepatide decision creates uncertainty for patients—and leads to a lawsuit

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Design by Adaptive Theme
Trimed Popup
Trimed Popup